ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Alloantibodies"

  • 2017 American Transplant Congress

    Non-Donor-Specific Anti-HLA Antibodies Have an Adverse Impact in Kidney Graft Outcomes.

    J. Malheiro,1 S. Tafulo,2 L. Dias,1 L. Martins,1 I. Beirão,1 A. Castro-Henriques.1

    1CHP, Porto, Portugal; 2IPST, Porto, Portugal

    Few studies have studied the impact of non-donor-specific antibodies (NDSA) in kidney transplantation (KT), with most showing no impact of these antibodies. As antibody-mediated graft…
  • 2017 American Transplant Congress

    APRIL/BLyS Inhibition Reduces Donor Specific Antibody in Sensitized Mice.

    B. Bolt, N. Wilson Schlei, B. Verhoven, R. Redfield.

    UW, Madison

    Background: Highly sensitized candidates on the kidney transplant waitlist remain a significant challenge as current desensitization protocols have variable success rates. Improved therapies are therefore…
  • 2017 American Transplant Congress

    Delayed Tolerance Induction Protocol for Vascularized Composite Allografts in Non-Human Primates: The Immunomodulatory Effect of Donor Bone Marrow Transplantation Does Not Prevent the Development of Chronic Rejection in the Absence of Durable Mixed Chimerism.

    Z. Ng, A. Lellouch, A.-R. Gama, I. Schol, I. Rosales, R. Colvin, L. Geoghegan, J. Kurtz, C. Cetrulo.

    Massachusetts General Hospital, Boston, MA

    PURPOSE: Donor bone marrow transplantation (DBMT) has been investigated in experimental and clinical vascularized composite allotransplantation (VCA). With longer-term follow-up, reports of chronic VCA rejection…
  • 2017 American Transplant Congress

    Emerging Safety and Tolerability of Obinutuzumab, a Type 2 Anti-CD20 Monoclonal Antibody for the Desensitization of Renal Transplant Candidates.

    R. Redfield,1 S. Jordan,2 T. Schindler,3 H. Tran,4 C. Looney,4 C. Green,4 A. Morimoto,4 R. Rajwanshi,4 M. Cascino,4 P. Brunetta,4 D. Borie.4

    1University of Wisconsin, Madison; 2Cedars-Sinai Medical Center, Los Angeles; 3F. Hoffmann-La Roche AG, Basel, Switzerland; 4Genentech, Inc., South San Francisco

    Background: Rituximab has limited efficacy for desensitizing allosensitized patients (pts) with end-stage renal disease (ESRD) and enabling kidney transplantation (KTx), however, tissue B-cell depletion is…
  • 2017 American Transplant Congress

    Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA Sensitized Patients Given Tacrolimus Once or Twice Daily During the First Two Years Post-Transplantation.

    N. Kamar, V. Hajj, I. Ferrandiz, E. Younes, L. Esposito, A. Hébral, A. Del Bello.

    Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France

    Donor-specific anti-HLA antibody (DSA)-mediated rejection (AMR) is a main cause of graft loss after kidney transplantation. Non-adherence is a risk factor for AMR and graft…
  • 2017 American Transplant Congress

    Correlation of Complement Activating Donor Specific Antibodies as Measured by C3d and Cross-Match Status.

    A. Babu,1,2,3 N. Krishnan,2 D. Briggs,3 D. Mitchell,1 S. Daga.1,2,4

    1Warwick Medical School, University of Warwick, Coventry, United Kingdom; 2Nephrology and Transplantation, University Hospitals Coventrya and Warwickshire, Coventry, United Kingdom; 3Histocompatibility and Immunogenetics, NHS Blood and Transfusion, Birmingham, United Kingdom; 4Nephrology and Transplantation, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Introduction. Complement dependent cytotoxicity, first described in 1969 is the only functional assay studying complement activation. C3d assay is developed recently to study complement activation…
  • 2017 American Transplant Congress

    Even with National Sharing, the Prospects of a 100% Sensitized Patient Receiving a Transplant Vary Dramatically Depending on the Precise CPRA Value.

    D. Stewart,1 A. Kucheryavaya,1 D. Tyan,2 H. Gebel,3 R. Bray,3 N. Turgeon.3

    1UNOS, Richmond, VA; 2Stanford Univ, Palo Alto, CA; 3Emory Univ Hosp, Atlanta, GA

    Background: In the Kidney Allocation System (KAS), CPRA of 99% & 100% candidates receive regional and national priority. This broader sharing, along with adoption of…
  • 2017 American Transplant Congress

    Risk Factors and Consequences of De Novo Anti-HLA Donor Specific Antibodies in Kidney Transplant Recipients: The Force Awakens.

    B. Javaid, S. Rosen-Bronson, D. Li, M. Awwad, A. Gilbert, S. Ghasemian, J. Verbesey, P. Abrams, M. Grafals, J. Fenton, C. Cannon, J. Rapisura, J. Moore, M. Cooper.

    Kidney and Pancreas Transplant Program, MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Georgetown University School of Medicine, Washington, DC

    Background: Presence of anti-HLA donor specific antibodies (DSAs) has been associated with inferior kidney transplant outcomes. Identification of risk factors for de novo DSAs could…
  • 2017 American Transplant Congress

    Does HLA Class of Complement Activating Donor Specific Antibodies Matter: Single Centre Retrospective Analysis of Renal Allograft Outcomes.

    A. Babu,1,2,3 D. Briggs,3 D. Mitchell,1 N. Krishnan,2 R. Higgins,1 S. Daga.1,2,4

    1Warwick Medical School, University of Warwick, Coventry, United Kingdom; 2Nephrology and Transplantation, University Hospitals Coventrya and Warwickshire, Coventry, United Kingdom; 3Histocompatibility and Immunogenetics, NHS Blood and Transfusion, Birmingham, United Kingdom; 4Nephrology and Transplantation, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Introduction. Complement activating donor specific antibodies may be associated with worse outcomes in a cohort of patients who have undergone HLA-AIT. We looked for differences…
  • 2017 American Transplant Congress

    Differential Suppressive Effects of Costimulatory Blockade (CD28/B7), Anti-IL6R, Bruton's Tyrosine Kinase and Janus Kinase Inhibition on De Novo vs. Recall Alloantibody Responses: Are Combined Drug Therapy Approaches Desirable?

    I. Kim, G. Wu, N.-N. Chai, A. Klein, S. Jordan.

    Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

    Purpose: Preformed and de novo donor specific antibodies (DSA) contribute significantly to demise of allograft functions. There is no approved therapies for prevention or treatment…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 40
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences